Dataset from A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009878
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and
maintaining testosterone suppression.
创建时间：
2025-02-10
